Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
27.76
+0.20 (0.74%)
Jun 5, 2025, 12:00 PM - Market open
Bright Minds Biosciences Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Bright Minds Biosciences stock ranges from a low of $75 to a high of $93. The average analyst price target of $83.25 forecasts a 199.95% increase in the stock price over the next year.
Price Target: $83.25 (+199.95%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Bright Minds Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $80 | Strong Buy | Maintains | $80 | +188.24% | May 21, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | May 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +188.24% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | +206.25% | Feb 19, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $93 | Buy | Initiates | $93 | +235.07% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.